FDA approved drug extends survival for patients with rare cancer

Sunitinib, an agent approved for use in several cancers, provides unprecedented antitumor activity in thymic carcinoma, a rare but aggressive tumor of the thymus gland, according to a phase II clinical trial.



from Today's Healthcare News -- ScienceDaily http://ift.tt/14X54vJ